Slay The Giant of Failure

Slaying the Giant of Failure

U will face Challenges but You will Overcome.

When You were in you’re  mothers womb you were already marked for Glory.
The Trade failed but that does not mean you are a failure.
In the eyes of Universal wonders of who we call God you are already a success.
One event does not make you a failure, as you’re Being is still intact.
Acknowledge what failure itself is, and do not deny it but face that giant and bring it down.
Accept Gods Forgiveness by forgiving You’re self sincerely and then try not too repeat the Mistake or find youre self going round and round in circles as life will continue to repeat the lesson till you learn it.
Apply the knowledge You got from that situation. and remember that Failure can be a good teacher but a bad master.
1: Be motivated by the benefits of every situation, Most people fail to overstand that there must circumstances, meaning
 (A condition or a fact that determines or must be considered in the determining a course of action) for success to be proven. As we know that in every problem there is the possibility for success. Therefore go beyond and transcend you’re mind by suspending natural laws to make his power manifest; that is how you make miracles happen.

2: Be Bold: David was bold and fearless when he faced Goliath ; Fore he understood that the kingdom of God suffers Violence Matthew 11:11-20
3: Overcome the Giant Complex; Nothing is to big for you to handle when you apply skill, persistence Smoothed  in due diligence. Draw upon you're victories of the past and draw on God.
Anything that becomes complex and scares you brings you under servitude,
4: Christians would say we are in the body of Christ and the world is his footstool. therefore  you must remember that we are more than Super Conquerors. Draw in the faithfulness that resides deep with in because that is where Heaven awaits you. Remember the days that you were pressed against the wall, down and out on the canvass, like you were in a rocky movie, but somehow the faithfulness of God pulled you through and made a way when there was no way out!!
Jehovah JEHOVAH-NISSI omnipotent power Be of good cheer; I have overcome the world" (John 16:33). The battle is not yours  alone but belongs to the Lord
Therefore use this when you meditate at the beginning of you're trading day and overcome you're trading demons.
5: You must not depend on flesh or and coat of arms for this will not save you. in the trading world risk management  coupled with discipline of 1 trade a day will keep you alive.
6: Follow and cry to the Lord for guidance.
Great that which is in me than those that are in the World anytime you are in the direction of success Satan will react to pull you off course and tempt you . Especially with the Holy spirit. remember  you are a carrier of destiny...Glory be to God
Those that belittle you shall be little, As Big things come in small sizes when victory comes  your way.

This is our season to overcome the Giant of failure.
In trading and in every thing else.
Now Mediate on these words and visualize you're victory.

The Bank of England made a "marked" increase to its near-term inflation forecast

 LONDON (Dow Jones)--The Bank of England made a "marked" increase to its near-term inflation forecast Wednesday, paving the way for earlier interest-rate rises than investors had expected.
        But a downgraded growth forecast balanced the picture, making some economists wary of forecasting near-term rate rises.
        The bank's quarterly Inflation Report pointed to the consumer price index rising by 5.0% later this year and only falling back to the 2.0% target in two years' time if the BOE raises interest rates five times, beginning in the third quarter of this year.
        "The May Inflation Report indicated that a rate hike this year is still on the agenda," said Simon Hayes, economist at Barclays Capital.
        Investors brought forward their expectations for rate increases in response. The sterling overnight index average rate, or Sonia, showed a 94% chance of a BOE rate rise in November, up from 84% before the bank published its report. Sonia, which indicates what banks expect to pay each other for short-term loans, fully priced in a rate increase as early as December, compared with January prior to the report.
        Investors in previous weeks had sharply pared back their forecasts for monetary policy tightening, following a string of weak U.K. economic data.
        In April, the Office for National Statistics estimated the economy grew by just 0.5% in the first three months of the year, only barely making up the for the 0.5% loss in output caused by heavy snow at the end of 2010. Private-sector surveys then pointed to a slowdown in April.
        But BOE Governor Mervyn King said the Monetary Policy Committee thinks the recent "softness" in economic output will prove temporary. The MPC also suggested in the report that U.K. output is being underestimated, and revisions to official data will show the economy in a stronger position.
        Barclays Capital's Hayes said that as long as activity appears stable, the MPC will return its focus to its sole mandate of keeping annual inflation at 2.0%.
        "Our perception is that the MPC has become increasingly uncomfortable with the fact that it keeps pushing out the point at which inflation returns to target, " he said.
        "The MPC's job is to deliver 2% inflation, not simply to forecast it, and the current policy setting looks increasingly unlikely to generate the necessary drop at any reasonable time horizon."
        The BOE said that if interest rates don't rise from their current all-time low of 0.5%, annual inflation will be above target two years from now. Price growth slowed to 4.0% in March, from 4.4% in February.
        King, in a press conference following the report's publication, also said high inflation now could push up wages and inflation expectations, making it that much more difficult to combat price growth.
        But some economists believe the BOE won't make any move to tighten policy until there is proof the economy has regained its footing.
        "We're looking at the economy losing traction in quite a serious way," said Ken Wattret, chief euro-zone economist at BNP Paribas.
        He predicted the BOE will look through the near-term rise in inflation. "If the BOE says inflation is going to hit 5% and it still isn't hiking rates, what will make them tighten in three months' time?"
        Wattret said that as long as uncertainty clouds the economic data, the MPC is likely to maintain its "wait-and-see" stance.
        The BOE's economic growth forecast in the inflation report was lower than in February. It also said the risks to growth are "skewed to the downside."
        King said slow growth is one consequence of the economy rebalancing to a more sustainable footing, away from financial services and domestic consumption and towards manufacturing and exports.
        Data Wednesday were encouraging on that front.
        The ONS said exports in the first quarter of 2011 rose 6.5% to GBP75.0 billion, the highest quarterly figure on record. That meant the first-quarter goods-trade deficit shrank to GBP22.2 billion, from 26.8 billion in the last three months of 2010.

        -By Alex Brittain, Dow Jones Newswires; +44 20 7842 9452; alex.brittain@dowjones.com

        (END) Dow Jones Newswires
        May 11, 2011 10:15 ET (14:15 GMT)

BioTime, Inc. (NYSE Amex:BTX) announced today

BioTime Initiates Clinical Development Program for HyStem®-Rx as a Cell Delivery Device for Reconstructive Surgery and Other Cell-Based Therapies
BioTime, Inc. (NYSE Amex:BTX) announced today that it has elected to seek regulatory approval of HyStem®-Rxas an implantable cell delivery vehicle that can be used to significantly improve outcomes in reconstructive surgery and potentially a wide array of other cell-based therapies. Such applications may include numerous cell transplant procedures currently being developed in which a patient's own adult stem cells are utilized. Similarly, once newer cell replacement products derived from human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells become available for medical use, HyStem®-Rx may provide the best means of implanting those cells in patients. Filing for regulatory approval of HyStem®-Rxas a medical device in Europe may begin within approximately 14 months, which is the estimated time for completing non-clinical studies and performing manufacturing and assay validations. Regulatory approval may take as few as two years, after which the product may be sold for use in existing cell transplant therapies.
HyStem®-Rx is a biocompatible hydrogel that mimics the extracellular matrix in which cells reside. As an injectable product, HyStem®-Rx may address an immediate need in cosmetic and reconstructive surgery and other procedures by improving the process of transplanting adipose (fat) cells or other adult stem cells. Adult stem cell types such as adipose stem cells obtained from a patient through liposuction can be transplanted back into the same patient in another location in the body, without the risk of rejection associated with the transplant of donor tissues. However, the transplantation of cells without the molecular matrix in which cells normally reside often leads to widespread cell death or the failure of the transplanted cells to remain in the transplant site. The transplant of cells in HyStem®-Rx may resolve these hurdles by localizing the transplanted cells in the intended location, and providing a three-dimensional form for the cells to rebuild normal tissue. HyStem®-Rx may have use in other emerging cell and tissue transplant therapies to treat osteoarthritis, brain tumors, stroke, bone fractures, and wounds.
"I have been following the development of the HyStem®-Rx hydrogel technology for some time," said J. William Futrell, M.D., Clinical Professor of Surgery at the University of Pittsburg, Adjunct Professor of Bioengineering at Carnegie-Mellon University, and Past President of the American Association of Plastic Surgeons. "HyStem®-Rx has tremendous potential as a biocompatible, resorbable matrix for the delivery of adipose-derived stem cells in the repair of subcutaneous contour defects arising from trauma, oncologic resection, and congenital defects and may prove a most significant advancement in stem cell therapies. I look forward to monitoring the Company's progress toward a CE Mark for HyStem®-Rx and its ultimate clinical use in reconstructive surgical procedures."
The use of HyStem®-Rx as an implantable cell delivery matrix in humans will require approval by government agencies that regulate the use of medical devices. BioTime expects to invest approximately $1.2 million during the next 12 to 14 months on more advanced non-clinical development of HyStem®-Rx, including additional biocompatibility, safety, and toxicity testing, and the performance of manufacturing and assay validations, with the plan to subsequently design and conduct clinical trials and apply for regulatory approval to market HyStem®-Rx as a medical device in countries outside the United States during the following two-year period. BioTime believes that it may be possible to obtain regulatory approval within the European Union and all other countries that accept the CE Mark with a total expenditure of between $3 million and $5 million, depending on clinical trial requirements and results.
"HyStem®-Rx as a device for the delivery of cells presents us with an opportunity to develop a new medical product that may be brought to market in a relatively short time frame and at a cost far less than that of products involving approval of new cell therapies," said Michael D. West, Ph.D., President and Chief Executive Officer of BioTime. "When combined with our pipeline of novel cell therapies, HyStem®-Rx provides a strategy for building significant revenues in both the near and long term, as the more advanced cell-based therapies come into use."
About BioTime, Inc.
BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is developed through subsidiaries focused on specific fields of applications. BioTime develops and markets research products in the field of stem cells and regenerative medicine, including a wide array of proprietary ACTCellerate™ cell lines, culture media, and differentiation kits. BioTime's wholly owned subsidiary ES Cell International Pte Ltd (ESI) has produced clinical-grade human embryonic stem cell lines that were derived following principles of Good Manufacturing Practice and currently offers them for use in research. BioTime's therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences, Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. Cell Cure's minority shareholder Teva Pharmaceutical Industries has an option to clinically develop and commercialize Cell Cure's OpRegen™ retinal cell product for use in the treatment of age-related macular degeneration (AMD). BioTime's subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic disorders and HyStem® hydrogel products for medical use and research. Another subsidiary, OncoCyte Corporation, focuses on the therapeutic applications of stem cell technology in cancer. ReCyte Therapeutics, Inc. is developing applications of BioTime's proprietary iPS cell technology to reverse the developmental aging of human cells to treat cardiovascular and blood cell diseases. BioTime's newest subsidiary, LifeMap Sciences, Inc., is developing an online database of the complex cell lineages arising from hES and iPS cells to guide basic research and to market BioTime's research products. In addition to its stem cell products, BioTime develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product, Hextend®, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements. Additional information about BioTime, ReCyte Therapeutics, Cell Cure, OrthoCyte, OncoCyte, BioTime Asia, and ESI can be found on the web at http://www.biotimeinc.com/.